Evidence map›Paper›PMID 42604258›Full record

ArticleMaterials today. Bio2026

Destroy and reconstruct: A microneedle platform for combined NIR-II photothermal therapy and asiaticoside-mediated tissue regeneration in cutaneous amyloidosis.

Zhiqiang Zhang, Long Chen, Chenxi Fang, Guoqiang You, Meitao Duan, Jungang Ren, Ming Chen, Chen Wang

Abstract read
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhiqiang ZhangResearch Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, 361023, PR China.
Long ChenResearch Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, 361023, PR China.
Chenxi FangResearch Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, 361023, PR China.
Guoqiang YouResearch Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, 361023, PR China.
Meitao DuanResearch Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, 361023, PR China.
Jungang RenResearch Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, 361023, PR China.
Ming ChenResearch Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, 361023, PR China.
Chen WangResearch Center for Sustained and Controlled Release Formulations, Xiamen Medical College, Xiamen, 361023, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous amyloidosis (CA) is a chronic skin disorder characterized by dermal amyloid deposition, accompanied by fibroblast hyperproliferation and keratinocyte apoptosis, yet current treatments are limited by poor transdermal delivery and inadequate lesion clearance. Here, we present a "destroy-reconstruct" strategy using dissolving microneedles (MNs) co-loaded with asiaticoside (AS) and a NIR-II photothermal agent (IR1048), modified with octaarginine (R8) for enhanced cellular uptake. The optimized AI-MN@R8 platform exhibited excellent mechanical strength, rapid

Indexed as

AsiaticosideCutaneous amyloidosisDissolving microneedlesEGFR/PI3K/AKT pathwayNIR-II photothermal therapy

Identifiers

PMID42604258
PMCPMC13476776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.